Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice
- PMID: 17570211
- DOI: 10.1053/j.gastro.2007.03.104
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice
Abstract
Background & aims: Interleukin (IL)-23 supports a distinct lineage of T cells producing IL-17 (Th17) that can mediate chronic inflammation. This study was performed to define the role of IL-23 and Th17 cells in chronic colitis in mice.
Methods: Colitis was induced by transfer of a cecal bacterial antigen-specific C3H/HeJBir (C3Bir) CD4(+) T-cell line to C3H/HeSnJ SCID mice. Cytokines were measured by flow cytometry, enzyme-linked immunosorbent assay, and real-time polymerase chain reaction. Monoclonal anti-IL-23p19 was administered at the same time as or 4 weeks after pathogenic CD4 T-cell transfer. A histopathology colitis score was assessed in a blinded fashion.
Results: The pathogenic C3Bir CD4(+) T-cell line contained more cells producing IL-17 than those producing interferon-gamma and these were distinct subsets; after adoptive transfer to SCID recipients, Th17 cells were predominant in the lamina propria of mice with colitis. Bacteria-reactive CD4(+) Th1 and Th17 lines were generated. The Th17 cells induced marked inflammation in a dose-dependent manner. Even at a dose as low as 10(4) cells/mouse, Th17 cells induced more severe disease than Th1 cells did at 10(6) cells/mouse. Monoclonal anti-IL-23p19 prevented and treated active colitis, with down-regulation of a broad array of inflammatory cytokines and chemokines in the colon. Anti-IL-23p19 induced apoptosis in colitogenic Th17 cells in vitro and in vivo.
Conclusions: Bacterial-reactive CD4(+) Th17 cells are potent effector cells in chronic colitis. Inhibition of IL-23p19 was effective in both prevention and treatment of active colitis. IL-23 is an attractive therapeutic target for inflammatory bowel disease.
Similar articles
-
Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.J Autoimmun. 2007 Sep-Nov;29(2-3):187-94. doi: 10.1016/j.jaut.2007.07.004. Epub 2007 Sep 5. J Autoimmun. 2007. PMID: 17804196
-
Regulation of gut inflammation and th17 cell response by interleukin-21.Gastroenterology. 2008 Apr;134(4):1038-48. doi: 10.1053/j.gastro.2008.01.041. Epub 2008 Jan 17. Gastroenterology. 2008. PMID: 18395085
-
Bone marrow retaining colitogenic CD4+ T cells may be a pathogenic reservoir for chronic colitis.Gastroenterology. 2007 Jan;132(1):176-89. doi: 10.1053/j.gastro.2006.10.035. Epub 2006 Oct 25. Gastroenterology. 2007. PMID: 17241870
-
Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.Curr Opin Gastroenterol. 2009 Jul;25(4):306-13. doi: 10.1097/MOG.0b013e32832bc627. Curr Opin Gastroenterol. 2009. PMID: 19448533 Review.
-
Targeting the development and effector functions of TH17 cells.Semin Immunol. 2007 Dec;19(6):383-93. doi: 10.1016/j.smim.2007.10.016. Epub 2008 Jan 14. Semin Immunol. 2007. PMID: 18083530 Review.
Cited by
-
Gut microbial metabolite deoxycholic acid facilitates Th17 differentiation through modulating cholesterol biosynthesis and participates in high-fat diet-associated colonic inflammation.Cell Biosci. 2023 Oct 3;13(1):186. doi: 10.1186/s13578-023-01109-0. Cell Biosci. 2023. PMID: 37789469 Free PMC article.
-
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):433-446. doi: 10.1038/s41575-023-00768-1. Epub 2023 Apr 17. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37069321 Free PMC article. Review.
-
Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic Implications.Int J Mol Sci. 2023 Feb 16;24(4):3957. doi: 10.3390/ijms24043957. Int J Mol Sci. 2023. PMID: 36835369 Free PMC article. Review.
-
Intestinal recruitment of CCR6-expressing Th17 cells by suppressing miR-681 alleviates endotoxemia-induced intestinal injury and reduces mortality.Inflamm Res. 2023 Apr;72(4):715-729. doi: 10.1007/s00011-023-01697-0. Epub 2023 Feb 7. Inflamm Res. 2023. PMID: 36749385
-
Epicutaneous Immunotherapy with CBir1 Alleviates Intestinal Inflammation.Inflamm Bowel Dis. 2023 May 2;29(5):798-807. doi: 10.1093/ibd/izac261. Inflamm Bowel Dis. 2023. PMID: 36651798 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials